|
|
|
|
Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint
Genentech announces topline results from Phase III trial of AvastinGenentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a ...ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates...
|
|
|
Unlocking cancer drug mechanism may avoid risk of birth defects
Scientists have uncovered how a drug used in blood cancer medicines leads to short or missing limbs in babies, moving closer to developing treatments without the risk of such birth defects.Thalidomide, the drug known for causing deformed arms and legs in...
|
|
|
Celgene Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released
Refer to a friend 2010-03-10 21:23:04 - Celgene Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com Celgene Corporation - Pharmaceuticals & Healthcare - Deals and Alliances...
|
|
|
Celgene Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report
www.companiesandmarkets.com/Summary-Company-Profile/celgene-corp ..Celgene Corporation - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the companys key business...
|
|
|
Best Practices in the Management of Newly Diagnosed Multiple Myeloma Patients Who Will Not Undergo Transplant
ABSTRACT:No survival advantage of autologous stem cell transplantation (ASCT) has been documented for patients older than 65 years, and in the era of thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid), ASCT has a diminished role in...
|
|
|
Reportlinker Adds Celgene Corporation: PharmaVitae Profile
NEW YORK, March 4 /PRNewswire/ -- Reportlinker.com announces that a new is available in its catalogue: http://www.reportlinker.com/p0180427/Celgene-Corporation-PharmaVitae-Profile.html Introduction This analysis examines the historical and forecast performance...
|
|
|
Reportlinker Adds Celgene Corporation: PharmaVitae Profile
This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical sector.The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales...
|
|
|
Myeloma Canada calls on Quebec government to approve Revlimid as second-line therapy
The Government of Quebec's Ministre de la sant et des services sociaux has approved the addition of Revlimid(R) (lenalidomide) to the Province's Drug Formulary as a third-line therapy for multiple myeloma patients.The cost of the drug will be reimbursed...
|
|
|
It's the End of Days for Celgene's Multiple-Myeloma Drug Franchise
Celgene (CELG) is counting on its blood-cancer drug Revlimid (lenalidomide)to support ambitious growth plans beyond its hematology-oncology franchise.However, the gravy train may be grinding to a halt much sooner than than most people think. Chief...
|
|
|
Celgene Sees 4Q Profit On Sales Boost, Lower Costs
SUMMIT, N.J.--Biotech drugmaker Celgene Corp.on Thursday reported a fourth-quarter profit on a boost in sales of the cancer drugs Revlimid and Vidaza, along with lower research and development costs. The Summit, N.J. company earned $254.2 million,...
|
|
|
Telik Initiates Ezatiostat Hydrochloride Phase 1 Study
Telik has initiated Phase 1 clinical study to evaluate ezatiostat hydrochloride (Telintra, TLK199) tablets in combination with lenalidomide (Revlimid) in patients with myelodysplastic syndrome (MDS).The Phase 1 trial is an open label, multicenter, dose...
|
|
|
Celgene completes acquisition of Gloucester Pharma
Celgene Corporation has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.Under the terms of the merger agreement Celgene...
|
|
|
Phase-III study of Revlimid by Intergroupe Francophone du Myelome & University Hospital of Toulouse meets prim
Celgene International Srl announced that the Intergroupe Francophone du Myelome and University Hospital of Toulouse, the sponsor of the study, reported that the independent Data and Safety Monitoring Committee, of the international phase-III, randomized, double...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 million Commercial Launch of Novel HDAC Inhibitor, ISTODAX (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010...
|
|
|
Celgene Completes Acquisition of Gloucester Pharmaceuticals
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG - News) today announced it has closed its acquisition of Gloucester Pharmaceuticals following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust...
|
|
|
Revlimid phase III trial in patients with multiple myeloma following autologous stem cell transplant meets pri
Celgene Corporation announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a phase-III, randomized, double-blind, multi-centre clinical study led by the Cancer and Leukaemia Group B (CALGB).The...
|
